Highlights ACADIA Pharmaceuticals Inc.

Equities

ACAD

US0042251084

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
16.71 ^USD	+2.45%		-0.65%	-46.63%

Apr. 23	Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada	MT
Apr. 22	Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada	Apr. 22	MT
Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada	Apr. 22	MT
Acadia Pharmaceuticals Inc Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada	Apr. 22	CI
ACADIA Pharmaceuticals Inc. Presents New DAYBUE (trofinetide) Clinical Data at the 2024 American Academy of Neurology Annual Meeting	Apr. 17	CI
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
Acadia Pharmaceuticals' schizophrenia drug fails in late-stage study	Mar. 11	RE
Acadia Pharmaceuticals Inc. Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia	Mar. 11	CI
Acadia Pharmaceuticals Q4 Swings to Profit, Revenue Increases -- Shares Fall After Hours	Feb. 27	MT
ACADIA Pharmaceuticals Inc. Provides Sales Guidance for the Full Year 2024	Feb. 27	CI
Earnings Flash (ACAD) ACADIA PHARMACEUTICALS Reports Q4 Revenue $231M, vs. Street Est of $223.8M	Feb. 27	MT
ACADIA Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
ACADIA Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight	Dec. 20	DJ
Acadia Pharmaceuticals Says Court Ruled in Company's Favor on Claims Related to Parkinson's Drug	Dec. 14	MT
Acadia Pharmaceuticals Shares Rise After Winning Summary Judgment in Nuplazid Patent Case	Dec. 13	MT
Acadia Pharmaceuticals Inc. Initiates Pivotal Phase 3 Study of Carbetocin (Acp-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome	Nov. 30	CI
Acadia Pharmaceuticals Inc. Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer's Disease Psychosis	Nov. 27	CI
ACADIA Pharmaceuticals Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023	Nov. 02	CI
Earnings Flash (ACAD) ACADIA PHARMACEUTICALS Reports Q3 Revenue $211.7M, vs. Street Est of $189.6M	Nov. 02	MT
ACADIA Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ACADIA Pharmaceuticals Inc.

Equities

ACAD

US0042251084

Highlights

Filters